3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
15
Unknown
4
Active not recruiting
3
Recruiting
2
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Breast Neoplasms
11
Lymphoma, Large B-Cell, Diffuse
10
Triple Negative Breast Neoplasms
8
Recurrence
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma, B-Cell
6
Neoplasm Metastasis
4
Multiple Myeloma
4
Leukemia, Myeloid, Acute
4
Leukemia
4
Neuroblastoma
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma
3
Hematologic Neoplasms
3
Head and Neck Neoplasms
3
Graft vs Host Disease
3
Squamous Cell Carcinoma of Head and Neck
2
Oropharyngeal Neoplasms
2
Neoplasms, Plasma Cell
2
Lymphoma, Follicular
2
Hodgkin Disease
2
Dendritic Cell Sarcoma, Interdigitating
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Wilms Tumor
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Interventions
Dexamethasone
2
daratumumab
1
belantamab mafodotin
1
Cyclophosphamide
1
Bortezomib
1
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Immunoglobulin Light-chain Amyloidosis
×
Cyclophosphamide
×
Clear all
NCT07224672
2026-03-17
ALANIS
GlaxoSmithKline
Phase 2
Not yet recruiting
60 enrolled